Background
==========

With the age of big data approaching \[[@B1]\], bioinformatics for Next-Generation Sequencing (NGS) and Genome-Wide Association Studies (GWAS) will be one of the biggest areas of disruptive innovation in life science tools over the next few years \[[@B2]\]. Next-Generation Sequencing technologies and Genome-Wide Association Studies generate millions of reads and hundreds of datasets, and there is an urgent need for a better way to accurately interpret and distill such large amounts of data. The use of large scale gene expression analysis has been proven to be useful in identifying differentially expressed genes to classify and predict various disease subtypes. However, it is often difficult to assign biological significance to a large number of genes that are implicated. This problem persists even when users are able to reduce the number of differentially expressed genes substantially via hierarchical clustering methods.

As more information is revealed through large-scale \"omics\" techniques, it is becoming increasingly apparent that genes do not function alone but through complex biological pathways. Unraveling these intricate pathways is essential to understanding biological mechanisms, disease states, and the function of drugs that transform them. Extensive pathway and network analysis allow for the discovery of highly significant pathways from a set of disease vs. healthy samples in the NGS and GWAS. Knowledge of activation of these processes will lead to elucidation of the complex biological pathways affected by drug treatment, to patient stratification studies of new and existing drug treatments, and to understanding the underlying anti-cancer drug effects.

Pathway databases serve as repositories of current knowledge on cell signaling, enzymatic reaction, and genetic regulation. There are more than 300 pathway repositories listed in Pathguide resource <http://www.pathguide.org>\[[@B3]\], from which over 141 are specialized on reactions in human as of Jan 2012, for example, BioCarta <http://www.biocarta.com>\[[@B4]\], KEGG <http://www.genome.jp/kegg/>\[[@B5]\], NCI-Nature curated <http://pid.nci.nih.gov/PID/index.shtml>\[[@B6]\], Reactome <http://www.reactome.org>\[[@B7]\], and Wikipathways <http://www.wikipathways.org/>\[[@B8]\]. However, these resources have several limitations. First, most currently available resources do not contain disease, drug or organ specificity information such as disease-pathway, drug-pathway, and organ-pathway associations. Next, these resources have been developed with variable degrees of data coverage, quality, and utility \[[@B9]\]. In addition, only half of them provide pathways and reactions in computer-readable formats needed for automatic retrieval and processing \[[@B10]\]. Lastly, many pathway databases are in distinct formats \[[@B11]\].

Systematic collection of pathway information not only in the form of pathway databases but also including inter-association between pathway, disease, drug, and organ specificity is crucial, because 1) it provides a bridge between pathway, disease, drug and organ, and 2) this bridge can not only capture relevant biological pathways but also provide disease, drug target, and organ specificity information. For \"inter-association\", we refer to a biological connection between two or more biological components on basis of intermediary genes (dotted lines in Figure [1](#F1){ref-type="fig"}).

![**Data Integration Process**. The whole data integration process was divided into three steps: 1) associations of molecule-pathway, molecule-disease, molecule-drug, molecule-organ; 2) inter-association analysis between pathway, disease, drug and organ; and 3) enrichment analysis and inter-association analysis: 3a) self-validation and 3b) identification of previously undiscovered components by the enrichment analysis.](1471-2105-13-S15-S7-1){#F1}

A component is a biomedical concept such as pathway, disease, drug and organ (nodes in Figure [1](#F1){ref-type="fig"}). Some pilot studies about this kind of connections have been done in the past. For example, Li et al. investigated disease relationships based on their shared pathways \[[@B12]\]. First, they extracted disease associated genes by literature mining. Then, they connected diseases to biological pathways through overlapping genes. Lastly, they built a disease network by connecting diseases sharing common pathways. Smith et al. combined pathway analysis and drug analysis to identify common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. Their study suggested that multiple and diverse respiratory viruses invoked several common host response pathways \[[@B13]\]. One study found that disease candidate genes were functionally related in the form of protein complexes or biological pathways and complex disease ensued from the malfunction of one or a few specific signaling pathways \[[@B14]\]. Another study aimed to explore complex relationships among diseases, drugs, genes, and target proteins altogether \[[@B15]\] and found that mapping the polypharmacology network onto the human disease-gene network revealed not only that drugs commonly acted on multiple targets but also that drug targets were often involved with multiple diseases. Berger and Iyengar also discussed how analysis of biological networks had contributed to the genesis of systems pharmacology and how these studies had improved global understanding of drug targets \[[@B16]\]. They described that an emerging area of pharmacology, systems pharmacology, which utilizes biological network analysis of drug action as one of its approaches, is becoming increasingly important in: providing new approaches for drug discovery for complex diseases; considering drug actions and side effects in the context of the regulatory networks within which the drug targets and disease gene products function; understanding the relationships between drug action and disease susceptibility genes; and increasing knowledge of the mechanisms underlying the multiple actions of drugs \[[@B16]\].

Therefore we created the [I]{.ul}ntegrated [P]{.ul}athway [A]{.ul}nalysis [D]{.ul}atabase for Systematic Enrichment Analysis (IPAD) for users to query information about genes, diseases, drugs, organ specificity, and signaling and metabolic pathways. First, we integrated data from four kinds of sources: 1) pathway databases from BioCarta \[[@B4]\], KEGG \[[@B5]\], NCI-Nature curated \[[@B6]\], and Reactome \[[@B7]\], 2) disease databases from CTD <http://ctdbase.org/>\[[@B17]\] and PharmGKB <http://www.pharmgkb.org>\[[@B18]\], 3) drug databases from DrugBank <httP://www.drugbank.ca>\[[@B19]\] and PharmGKB \[[@B18]\], and 4) organ-specific genes/proteins from HOMER <http://discern.uits.iu.edu:8340/Homer/index.html>\[[@B20]\]. Next, we created inter-association between pathway, disease, drug, and organ specificity. Then, we built a web interface for users to perform 1) enrichment analysis from genes/proteins/molecules, and 2) inter-association analysis from a pathway, disease, drug and organ. Lastly, we presented three case studies: 1) breast cancer related markers, 2) brain-specific markers, and 3) prostate cancer model to demonstrate that the IPAD can enable users to analyze enrichment and inter-association between pathway, disease, drug and organ, to discover previously undiscovered pathway, disease, drug and organ, and to validate the enrichments.

The Integrated Pathway Analysis Database for Systematic Enrichment Analysis (IPAD), located at <http://bioinfo.hsc.unt.edu/ipad> is a comprehensive database covering about 22,498 genes, 25,469 proteins, 1956 pathways, 6704 diseases, 5615 drugs, and 52 organs integrated from databases including the BioCarta \[[@B4]\], KEGG \[[@B5]\], NCI-Nature curated \[[@B6]\], Reactome \[[@B7]\], CTD \[[@B17]\], PharmGKB \[[@B18]\], DrugBank \[[@B19]\], PharmGKB \[[@B18]\], and HOMER \[[@B20]\].

It is the first comprehensive database that can be used to analyze, discover, and validate enrichment and inter-association between pathway, disease, drug and organ. The inter-associations allow further identification of enriched pathways, diseases, drugs and organs. The quality of the database is validated on a \"gold standard\" constructed from reputable and reliable sources. The ability to choose multiple quantitative parameters (p-value, Absolute Enrichment Value (AE), Relative Enrichment Value (RE), and Mean Jaccard Index (MJI)) provides us with powerful statistics and computation to accurately calculate enrichment and inter-association. And the cross-linking of multiple data sources enables subsequent validation.

Results
=======

Database content statistics
---------------------------

By integrating pathway, disease, drug, and organ specificity databases including BioCarta \[[@B4]\], KEGG \[[@B5]\], NCI-Nature curated \[[@B6]\], Reactome \[[@B7]\], CTD \[[@B17]\], PharmGKB \[[@B18]\], DrugBank \[[@B19]\], and Homer \[[@B20]\], we have developed IPAD, the [I]{.ul}ntegrated [P]{.ul}athway [A]{.ul}nalysis [D]{.ul}atabase for systematic enrichment analysis. As of the current release (May 2012), IPAD contains 25,469 proteins (IPI IDs), 22,498 genes (gene IDs), 1956 pathways covering 11663 genes, 6,704 diseases covering 17925 genes, 5,615 drugs covering 3735 genes, and 52 organs covering 5599 genes (Table [1](#T1){ref-type="table"}). A comparison of pathways in IPAD against several common pathway data sources is shown in Table [2](#T2){ref-type="table"}.

###### 

Current Statistics of Database

  Total Number           Count
  ---------------------- ---------------------------------------------------------------------
  genes                  22,498 GeneIDs
  proteins               25,469 UniProtIDs
  Pathways               1956 (BioCarta:310,KEGG:247, NCI-Nature curated:222, Reactome:1177)
  Molecules in Pathway   11663
  Diseases               6704(CTD:5892, PharmGKB:812)
  Molecules in Disease   17925
  Drugs                  5615(DrugBank:4604, PharmGKB:1011)
  Molecules in Drug      3735
  Organs                 52
  Molecules in Organ     5599

###### 

A Comparison of Human Pathways in IPAD against Several Common Pathway Data Sources

                                    **BioCarta**\[[@B4]\]   **KEGG**\[[@B5]\]   **NCI-Nature curated**\[[@B6]\]   **Reactome**\[[@B7]\]   IPAD
  --------------------------------- ----------------------- ------------------- --------------------------------- ----------------------- ------------
  Pathway coverage                  310                     247                 222                               1177                    1956
  Molecule coverage                 1372                    9238                2561                              5668                    11663
  Last Updated                      2010                    Mar 2012            July 2010                         Jan 2011                Mar 2012
  Curation Type                     Manual                  Manual              Manual                            Manual                  Integrated
  Disease Association               No                      Yes                 No                                No                      Yes
  Drug Association                  No                      Yes                 No                                No                      Yes
  Organ Specificity Association     No                      No                  No                                No                      Yes
  Inter-associations Quantitative   No                      No                  No                                No                      Yes
  Enrichment Score Quantitative     No                      No                  No                                No                      Yes
  Similarity                        No                      No                  No                                No                      Yes

P-value distribution of inter-association
-----------------------------------------

We performed statistical testing using p-value described in the method section to describe the inter-association between pathway, disease, drug and organ in IPAD (Figure [2a](#F2){ref-type="fig"} and Figure [2b](#F2){ref-type="fig"}). Although the majority of associations are not significant (p-value close to 1), there are still some which are significant (p-value ≤ 10^-5^). Component similarity can also be measured by Absolute Expression Value (AE), Relative Expression Value (RE) and Mean Jaccard Index (MJI). The four measurements (p-value, AE, RE, MJI) can complement each other and compensate for the weaknesses inherent in each alone to create better criteria for enrichment analysis.

![**p-value Distribution of Inter-association**. The y-axis is the scaled density of p-value which is calculated by Fisher Exact test. (a) p-value Distribution of Inter-association between pathway-pathway, disease-disease, drug-drug, and organ-organ. (b) p-value Distribution of Inter-association between pathway, disease, drug, and organ.](1471-2105-13-S15-S7-2){#F2}

The inter-association between the 52 organs in Figure [3](#F3){ref-type="fig"} shows that the heart and muscle have strongest association with a smallest p-value:2.51e-7 (1-log10p-value = 7.6) and 14 genes in common. The other strong associations occur between spleen and liver (20 genes in common, p-value = 1.69e-6, and 1-log10p-value = 6.77), and bone marrow and bone (7 genes in common, p-value = 2.15e-4, and 1-log10p-value = 4.67).

![**Heatmap of Inter-associations between 52 Organs**. x-axis and y-axis are both 52 organs. The degrees of redness and blackness in each cell represent increase of association between organs. The legend above the heatmap indicates the range of association between organs. The association between organs is expressed by 1 minus log10 of p-value. It is nonlinear color scale from white to red to black, correspondingly, indicating the value of 1-log10(p-value) scales from 1 to 7.6.](1471-2105-13-S15-S7-3){#F3}

General online features
-----------------------

In Figure [4](#F4){ref-type="fig"}, we show the user interfaces of the web-based online version of IPAD. It supports standard and powerful search options that allow users to specify a list of genes/proteins as the query input. Some interesting features of IPAD include the ability to browse for pathway, disease, drug, and organ with tabs in one page, search by keyword in the Search Box over the table, and set the p-value cutoff in the enrichment threshold box to select enriched pathway sets, disease sets, drug sets and organ sets.

![**Web Interface Structure**. a) Query by genes or proteins. For example, UniGene IDs, Entrez gene IDs, gene names, UniProt IDs, UniProt Accessions or IPI IDs are all supported. To enter multiple values, delimit them by comma, semi-colon, line or space. b,c,d,e) search result. In the enrichment analysis table, it shows Pathway ID (Disease ID, Drug ID, Organ ID), Pathway Name (Disease Name, Drug Name, Organ Name), Molecule, significance (AE, RE, N, MJI, p-value), and inter-association. For each enriched component, users can further browse the inter-association between its molecule and pathway, disease, drug and organ by clicking on the link in the column of molecule, and its inter-association between pathway, disease, drug and organ by clicking on the inter-association icon in the last column. f) molecule inter-association. It shows molecule, Gene Symbol, Pathway ID (Disease ID, Drug ID, Organ ID), and Pathway Name (Disease Name, Drug Name, Organ Name). g,h,i,j) inter-association between pathway, disease, drug and organ. It shows associations between Pathway-Pathway, Pathway-Disease, Pathway-Drug, Pathway-Organ, Disease-Pathway, Disease-Disease, Disease-Drug, Disease-Organ, Drug-Pathway, Drug-Disease, Drug-Drug, Drug-Organ, Organ-Pathway, Organ-Disease, Organ-Drug, Organ-Organ, and their significance (AE, RE, MJI, p-value).](1471-2105-13-S15-S7-4){#F4}

In response to the query input, IPAD can retrieve a list of related components (pathways, diseases, drugs, and organs) in a highly flexible table, with which users can further explore details about inter-association between the components. For example, users can browse the inter-association between each component\'s molecule and pathway, disease, drug and organ by clicking on the link in the column of molecule, and look through the component-related inter-association between pathway, disease, drug and organ by clicking on the inter-association icon in the last column. There are totally sixteen types of inter-associations between pathway, disease, drug and organ in IPAD: Pathway-Pathway, Pathway-Disease, Pathway-Drug, Pathway-Organ, Disease-Pathway, Disease-Disease, Disease-Drug, Disease-Organ, Drug-Pathway, Drug-Disease, Drug-Drug, Drug-Organ, Organ-Pathway, Organ-Disease, Organ-Drug, and Organ-Organ. User queried inter-association pathway/disease/drug/organ data stored in IPAD can also be freely downloaded as tab-delimited text files using links below each enrichment or inter-association table.

Assessment of IPAD
------------------

Assessing the capabilities of any pathway/disease/drug/organ enrichment analysis in real experiments is a challenge in itself because the full truth of what really occurred between the components and how they are actually inter-associated, if at all, may never be known. In the absence of a \"gold standard\" - a reference standard against which to establish the performance of the filter, the best alternative is to analyze the results of the enrichment analysis method in the context of the existing biological knowledge \[[@B21]\]. We first used two identified studies to illustrate how well the significant pathways/diseases/drugs/organs identified by the enrichment analysis and inter-association analysis of IPAD fit with the existing biological knowledge. Then we constructed a \"gold standard\" of 30161 known associations and used it to assess the inter-association analysis of IPAD.

Assessment of enrichment analysis
---------------------------------

The absence of a definitive answer regarding the involvement of a particular pathway/disease/drug/organ in a given condition makes it impossible to calculate exact values for sensitivity, specificity, ROCs, etc. Therefore, we compared the result of IPAD\'s enrichment analysis and inter-association analysis and tested whether the significant pathways/diseases/drugs/organs fit with the existing biological context. This type of assessment is the current best practice in this area of enrichment analysis \[[@B22]\].

In the first dataset, we assessed the features of IPAD by testing the inter-association between breast cancer markers related pathway, disease, drug and organ. Breast cancer is a cancer that starts in the tissues of the breast. We first downloaded the 15 breast cancer related genes from the Cancer Gene Census \[[@B23]\]: AKT1, BAP1, BRCA2, CCND1, CDH1, EP300, ERBB2, ETV6, GATA3, MAP2K4, NTRK3, PBRM1, PIK3CA, RB1, and TP53. The top 5 associated drugs (p-value ≤ 9.9 × 10^-3^, *AE*≥ 2.57, *RE*≥ 13.51 and *MJI*≥ 0.154; PA451581 tamoxifen, PA131301952 gefitinib, PA152241907 lapatinib, PA449509 estrogens, and PA449383 docetaxel) we identified using IPAD are all reportedly linked to breast cancer by previously published papers (Table [3](#T3){ref-type="table"}). For example, most women with estrogen-sensitive breast cancer benefit from the drug tamoxifen \[[@B24]\]. This drug blocks the effects of estrogen, which can help breast cancer cells survive and grow. Green et al. tested whether Gefinitib as an orally active selective EGFR inhibitor might benefit advanced breast cancer (ABC) patients either with acquired hormone resistance or with hormone receptor (HR)-negative tumors. They concluded that at a dose of 500 mg/day, gefitinib monotherapy resulted in a low Clinical Benefit Rate (CBR) and no tumor response was identified \[[@B25]\]. Lapatinib is used as a treatment for treatment-naive women with breast cancer, ER+/EGFR+/HER2+ breast cancer patients (now often called \"triple positive\") and patients who have HER2-positive advanced breast cancer that has progressed after previous treatment with other chemotherapeutic agents, such as anthracycline, taxane-derived drugs, or trastuzumab \[[@B26]\]. Estrogen is a hormone that is necessary for the normal development and growth of the breasts and organs important for childbearing. For example, several weeks after a study suggested that women who take estrogen-only hormone replacement to treat menopause symptoms may be at lower risk for developing breast cancer, another, much-larger study found that when used for longer than 10 years, estrogen-only regimens actually raise a woman\'s long-term risk for breast cancer \[[@B27]\]. Docetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer. For example, Martin et al. compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer and found that adjuvant chemotherapy with TAC significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer \[[@B28]\].

###### 

Enrichment Analysis of Breast Cancer Related Markers

  PathwayID          PathwayName                                                              N       P-value       AE       RE       MJI
  ------------------ ------------------------------------------------------------------------ ------- ------------- -------- -------- ---------
  hsa05212           Pancreatic cancer                                                        72      3.74E-08      7        75.59    0.2819
  hsa05213           Endometrial cancer                                                       53      1.07E-07      6        88.02    0.2566
  hsa05215           Prostate cancer                                                          100     1.07E-07      7        54.43    0.2683
  hsa05223           Non-small cell lung cancer                                               60      1.60E-07      6        77.75    0.25
  hsa05218           Melanoma                                                                 72      3.55E-07      6        64.79    0.2417
  hsa05200           Pathways in cancer                                                       348     1.02E-06      9        20.11    0.3129
  hsa05219           Bladder cancer                                                           42      1.02E-06      5        92.56    0.2262
  h_RacCycDPathway   Influence of Ras and Rho proteins on G1 to S Transition                  26      6.66E-06      4        119.62   0.2103
  hsa05214           Glioma                                                                   69      6.66E-06      5        56.34    0.2029
  hsa05220           Chronic myeloid leukemia                                                 74      7.91E-06      5        52.54    0.2005
  hsa05166           HTLV-I infection                                                         272     1.71E-05      7        20.01    0.2462
  hsa05222           Small cell lung cancer                                                   90      1.71E-05      5        43.2     0.1944
  200124             E-cadherin signaling in the nascent adherens junction                    39      2.10E-05      4        79.75    0.1846
  200141             FOXM1 transcription factor network                                       41      2.37E-05      4        75.86    0.1821
  200190             a6b1 and a6b4 Integrin signaling                                         46      3.40E-05      4        67.61    0.1768
  hsa04110           Cell cycle                                                               124     5.80E-05      5        31.35    0.1868
  hsa05210           Colorectal cancer                                                        62      8.23E-05      4        50.16    0.1656
  200041             Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)   80      1.67E-05      4        38.88    0.1583
                                                                                                                                      
  **DiseaseID**      **DiseaseName**                                                          **N**   **P-value**   **AE**   **RE**   **MJI**
                                                                                                                                      
  MESH:D002528       Cerebellar Neoplasms                                                     332     6.34E-07      9        32.39    0.3136
  MESH:D020967       Myotonic Disorders                                                       278     1.87E-05      7        30.09    0.2459
  MESH:D042883       Choledocholithiasis                                                      157     1.87E-05      6        45.67    0.2191
  MESH:D002282       Adenocarcinoma, Bronchiolo-Alveolar                                      339     3.44E-05      7        24.68    0.2437
  MESH:D009134       Muscular Atrophy, Spinal                                                 1119    3.44E-05      11       11.75    0.3716
  MESH:D016510       Corneal Neovascularization                                               669     3.44E-05      9        16.08    0.3067
  MESH:D044483       Intestinal Polyposis                                                     120     4.42E-05      5        49.79    0.1875
  PA443756           Colonic Neoplasms                                                        122     4.42E-05      5        48.98    0.1872
  PA445062           Neoplasms                                                                237     4.42E-05      6        30.25    0.2127
  MESH:D007972       Leukoplakia, Oral                                                        238     4.42E-05      6        30.13    0.2126
  MESH:D003123       Colorectal Neoplasms, Hereditary Nonpolyposis                            126     4.42E-05      5        47.42    0.1865
  MESH:D046152       Gastrointestinal Stromal Tumors                                          148     8.01E-05      5        40.37    0.1836
                                                                                                                                      
  **DrugID**         **DrugName**                                                             **N**   **P-value**   **AE**   **RE**   **MJI**
                                                                                                                                      
  PA451581           tamoxifen                                                                74      1.83E-03      5        18.03    0.2124
  PA131301952        gefitinib                                                                39      1.83E-03      4        27.36    0.1941
  PA152241907        lapatinib                                                                14      1.83E-03      3        57.17    0.2143
  PA449383           docetaxel                                                                77      9.81E-03      4        13.86    0.1688
  PA449509           estrogens                                                                79      9.89E-03      4        13.51    0.1682
                                                                                                                                      
  **OrganID**        **OrganName**                                                            **N**   **P-value**   **AE**   **RE**   **MJI**
                                                                                                                                      
  larynx             larynx                                                                   88      1.97E-2       2        25.45    0.2114

By the pathway analysis (p-value ≤ 1.69 × 10^-4^, *AE*≥ 3.03, *RE*≥ 20.01 and *MJI*≥ 0.158), we identified 18 associated pathways of which most are linked with cancer such as hsa05212 Pancreatic cancer, hsa05213 Endometrial cancer, hsa05215 Prostate cancer, hsa05223 Non-small cell lung cancer, hsa05218 Melanoma, hsa05219 Bladder cancer, hsa05200 Pathways in cancer, hsa05214 Glioma, hsa05220 Chronic myeloid leukemia, hsa05222 Small cell lung cancer, and hsa05210 Colorectal cancer (Table [3](#T3){ref-type="table"}). We also discovered 107 diseases (p-value ≤ 1.59 × 10^-4^, *AE*≥ 4.35, *RE*≥ 6.31 and *MJI*≥ 0.17, Table [3](#T3){ref-type="table"}, the top 12 diseases were shown due to space limitation). Most of them are linked with cancer such as MESH:D002528 Cerebellar Neoplasms, MESH:D016510 Corneal Neovascularization, MESH:D002282 Adenocarcinoma, Bronchiolo-Alveolar, MESH:D044483 Intestinal Polyposis, PA443756 Colonic Neoplasms, PA445062 Neoplasms, MESH:D003123 Colorectal Neoplasms, Hereditary Nonpolyposis, and MESH:D046152 Gastrointestinal Stromal Tumors.

By the inter-association, we found that the number 1 pathway (hsa05212, pancreatic cancer) we identified from the enrichment analysis is also highly associated with the pathway (hsa05200, pathways in cancer, p-value = 3.04 × 10^-66^, 46 orders of magnitude more significant than the pathway-pathway p-value threshold 2.13 × 10^-19^), disease (MESH:D046152 Gastrointestinal Stromal Tumors, p-value = 1.89 × 10^-32^, 25 orders of magnitude more significant than the pathway-disease p-value threshold 1.28 × 10^-6^), and drug (PA450191 lecithin, p-value = 4.55 × 10^-11^, 7 orders of magnitude more significant than the pathway-drug p-value threshold 5.73 × 10^-4^). Highly is measured by p-value. When the individual p-values are at least three orders of magnitude lower than current used p-value threshold, they are called \"highly significant.\"

The pathway \"hsa05200, pathways in cancer\" and disease \"MESH:D046152 Gastrointestinal Stromal Tumors\" are already included in our previous enrichment analysis and were validated by the inter-association analysis. The drug PA450191 lecithin was filtered out in the enrichment analysis due to its insignificant measurement (p-value = 0.0472, AE = 2, RE = 9.04, MJI = 0.0884) and was discovered by the inter-association analysis as a previously undiscovered drug (p-value = 4.55 × 10^-11^, AE = 14, RE = 14.53, MJI = 0.2334). Similarly, the number 1 disease (MESH:D002528 Cerebellar Neoplasms) was found to be inter-associated with hsa05200 Pathways in cancer (validated, p-value = 6.86 × 10^-42^, AE = 79, RE = 9.39, MJI = 0.2536), MESH:D016410 Lymphoma, T-Cell, Cutaneous (previously undiscovered, p-value = 3.76 × 10^-100^, AE = 320, RE = 6.15, MJI = 0.5389), and PA449780 glutathione (previously undiscovered, p-value = 4.41 × 10^-18^, AE = 37, RE = 8.20, MJI = 0.3173); and the number 1 drug (PA451581 tamoxifen) was found to be inter-associated with 211859 Biological oxidations (previously undiscovered, p-value = 9.31 × 10^-25^, AE = 24, RE = 30.06, MJI = 0.2654), PA443560 Breast Neoplasms (previously undiscovered, p-value = 3.26 × 10^-50^, AE = 49, RE = 35.43, MJI = 0.4042), and PA449503 estradiol (previously undiscovered, p-value = 1.2 × 10^-21^, AE = 30, RE = 15.45, MJI = 0.3558).

Another dataset we used to assess the enrichment analysis is with the \"self-validation\" in Case Study 1. The self-validation makes the result of enrichment analysis more reliable and meaningful and consistent with the existing biological context. If a result of enrichment analysis can be validated by its subsequent inter-association analysis, it is also validated that the enrichment analysis and inter-association analysis are consistent and are both somewhat reliable.

Assessment of inter-associated analysis
---------------------------------------

We constructed a \"gold standard\" of 30161 inter-associations (247 Pathway-Drug; 274 Drug-Drug; 23659 Pathway-Disease; 405 Organ-Disease; 2826 Drug-Disease; 2750 Disease-Disease) from KEGG \[[@B5]\], CTD \[[@B17]\], PharmGKB \[[@B18]\], DrugBank \[[@B19]\], and Disease Ontology <http://do-wiki.nubic.northwestern.edu/do-wiki/index.php/Main_Page>\[[@B29]\]. We evaluated the performance of inter-association analysis method for the above six types of inter-associations (Figure [5](#F5){ref-type="fig"}). Pathway-Disease inter-associations have the highest specificity (92.4%), and Organ-Disease inter-associations have the highest sensitivity (87.9%) and F_measure (78.4%).

![**Assessment of Different Associations**. The bar plot shows sensitivity, specificity, prediction, accuracy, and F_measure of pathway-drug, drug-drug, pathway-disease, organ-disease, drug-disease, disease-disease, and all associations as a whole.](1471-2105-13-S15-S7-5){#F5}

Compared to sensitivity, specificity and accuracy, the prediction rates are relatively low because the size of testing set are much larger than that of the \"gold standard\" set. When more \"gold standards\" of inter-associations become available in the future, the prediction rates and F_measure can be improved because the currently unpredicted pairs will be able to be predicted correctly. Figure [5](#F5){ref-type="fig"} also gives a global evaluation for all 30161 inter-associations (Precision 60.73%, Accuracy 89.90%, Sensitivity 78.69%, Specificity 91.72%, F_measure 68.56%). Overall, the balanced F_measure (68.56%) shows our inter-association analysis method is reliable and can be used for further enrichment analysis.

Case Studies
============

We show two case studies of increasing complexity and biological significance to achieve two goals: 1) to demonstrate the IPAD\'s ability to self-validate by using it to perform enrichment analysis and inter-association analysis on the 369 brain-specific markers, and 2) to demonstrate the ability of IPAD to identify previously undiscovered components by the enrichment analysis based on differentially expressed genes identified from a prostate cancer study.

Case Study 1: Self-validation with inter-association analysis
-------------------------------------------------------------

The highly associated relationships between pathway, disease, drug and organ can be used to validate the identified enriched pathway, disease, drug and organ candidates. The more dense and complex the inter-association between the four components, the more reliable and robust the identified candidates. In order to demonstrate the self-validation of IPAD, we first performed enrichment analysis on the 369 brain-specific markers we extracted from Homer \[[@B20]\] and then used the inter-association analysis in IPAD to validate the traditional enrichment analysis. We identified 16 enriched pathways (p-value ≤ 5.67 × 10^56^, *AE*≥ 4.86, *RE*≥ 7.42 and *MJI*≥ 0. 107), 92 enriched diseases (p-value ≤ 4.52 × 10^-7^, *AE*≥ 28.55, *RE*≥ 1.31 and *MJI*≥ 0.10), 7 enriched drugs (p-value ≤ 2.49 × 10^-7^, *AE*≥ 8.06, *RE*≥ 26.98 and *MJI*≥ 0.30), and 1 enriched organ (p-value ≤ 0.05, *AE*≥ 260, *RE*≥ 15.42 and *MJI*≥ 0.85) (Table [4](#T4){ref-type="table"}, only 10 diseases are shown due to space limitation). All components were validated by the inter-association analysis except that only 88 out of 92 diseases were validated. Due to space limitation, we selected the top 10 diseases and other components to draw a circular view. The circular view of the 16 pathways, 7 drugs, 1 organ and top 10 diseases shows that all these 34 components are inter-associated with at least one other component (Figure [6](#F6){ref-type="fig"}). The table visualization was created by the tableviewer utility script, which is included in Circos \[[@B30]\]. We set the four text colors: palegreen, chocolate, royalblue, and magenta which stand for the four components: pathway, disease, drug, and organ, respectively. We transformed the extent of association between two components by using 1 minus log10 of p-value and set links with variable thickness representing the extent of inter-associations. The direction of association (A-\>B) is represented by a ribbon\'s end touching A and its other end not touching B.

###### 

Enrichment Analysis of Brain-Specific Markers

  Rank       PathwayID       PathwayName                                                                              N       Pvalue       AE       RE       MJI
  ---------- --------------- ---------------------------------------------------------------------------------------- ------- ------------ -------- -------- ---------
  1          112315          Transmission across Chemical Synapses                                                    190     0            27       17.26    0.2117
  2          112316          Neuronal System                                                                          283     0            32       13.74    0.2232
  3          hsa04723        Retrograde endocannabinoid signaling                                                     116     4.68E-14     18       18.85    0.1713
  4          112314          Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell   136     4.48E-13     18       16.08    0.1599
  5          hsa04727        GABAergic synapse                                                                        98      5.48E-13     16       19.84    0.165
  6          hsa04080        Neuroactive ligand-receptor interaction                                                  401     4.42E-12     26       7.88     0.1678
  7          977441          GABA A receptor activation                                                               12      7.38E-09     7        70.87    0.3281
  8          975298          Ligand-gated ion channel transport                                                       25      1.41E-08     8        38.88    0.2017
  9          977443          GABA receptor activation                                                                 53      1.30E-07     9        20.63    0.1318
  10         hsa04724        Glutamatergic synapse                                                                    134     2.62E-07     12       10.88    0.1073
  11         983712          Ion channel transport                                                                    61      3.20E-07     9        17.92    0.1206
  12         420499          Class C/3 (Metabotropic glutamate/pheromone receptors)                                   15      5.19E-07     6        48.6     0.2313
  13         888590          GABA synthesis, release, reuptake and degradation                                        19      1.52E-06     6        38.37    0.1891
  14         399719          Trafficking of AMPA receptors                                                            30      1.33E-05     6        24.3     0.1313
  15         399721          Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity                  30      1.33E-05     6        24.3     0.1313
  16         112310          Neurotransmitter Release Cycle                                                           36      3.03E-05     6        20.25    0.1146
                                                                                                                                                             
  **Rank**   **DiseaseID**   **DiseaseName**                                                                          **N**   **Pvalue**   **AE**   **RE**   **MJI**
                                                                                                                                                             
  1          MESH:D001764    Blepharospasm                                                                            699     0            45       5.52     0.1398
  2          MESH:D012563    Schizophrenia, Paranoid                                                                  649     3.18E-12     40       5.29     0.1265
  3          MESH:D002385    Cataplexy                                                                                723     1.33E-11     41       4.86     0.1264
  4          MESH:D020187    REM Sleep Behavior Disorder                                                              506     1.44E-11     34       5.76     0.1149
  5          MESH:D020821    Dystonic Disorders                                                                       837     4.52E-10     41       4.2      0.1226
  6          MESH:D015877    Miosis                                                                                   1000    1.94E-09     44       3.77     0.1273
  7          MESH:D001925    Brain Damage, Chronic                                                                    1732    1.20E-08     59       2.92     0.1582
  8          MESH:D000341    Affective Disorders, Psychotic                                                           700     1.50E-08     34       4.17     0.1056
  9          MESH:D007415    Intestinal Obstruction                                                                   1293    2.33E-08     48       3.18     0.1334
  10         MESH:D011681    Pupil Disorders                                                                          1612    2.61E-08     55       2.93     0.1486
                                                                                                                                                             
  **Rank**   **DrugID**      **DrugName**                                                                             **N**   **Pvalue**   **AE**   **RE**   **MJI**
                                                                                                                                                             
  1          DB01595         Nitrazepam                                                                               20      2.92E-08     10       29.64    0.3294
  2          DB00349         Clobazam                                                                                 19      4.26E-08     9        28.08    0.3083
  3          DB00475         Chlordiazepoxide                                                                         19      4.26E-08     9        28.08    0.3083
  4          DB00683         Midazolam                                                                                19      4.26E-08     9        28.08    0.3083
  5          DB00690         Flurazepam                                                                               19      4.26E-08     9        28.08    0.3083
  6          DB00842         Oxazepam                                                                                 19      4.26E-08     9        28.08    0.3083
  7          DB01558         Bromazepam                                                                               19      4.26E-08     9        28.08    0.3083
                                                                                                                                                             
  **Rank**   **OrganID**     **OrganName**                                                                            **N**   **Pvalue**   **AE**   **RE**   **MJI**
                                                                                                                                                             
  1          brain           brain                                                                                    363     0            260      15.42    0.8581

![**A Circular View of the Inter-association Analysis of 369 Brain-Specific Markers**. The text colors for the four components: pathway, disease, drug, and organ are palegreen, Chocolate, royalblue, and magenta, respectively. Links with variable thickness represent the extent of association between two components which is 1 minus log10 of p-value. The direction of association (A-\>B) is represented by a ribbon\'s end touching A and its other end not touching B.](1471-2105-13-S15-S7-6){#F6}

The 10 identified diseases: 1) MESH:D001764, Blepharospasm, 2) MESH:D012563, Schizophrenia, Paranoid, 3) MESH:D002385, Cataplexy, 4) MESH:D020187, REM Sleep Behavior Disorder, 5) MESH:D020821, Dystonic Disorders, 6) MESH:D015877, Miosis, 7) MESH:D001925, Brain Damage, Chronic, 8) MESH:D000341, Affective Disorders, Psychotic, 9) MESH:D007415, Intestinal Obstruction, and 10) MESH:D011681, Pupil Disorders, have on average 766 inter-associations between pathway, disease, drug and organ, which shows a strong association with those 369 brain-specific markers.

A blepharospasm is any abnormal contraction or twitch of the eyelid. There have been several important advances in understanding the brain mechanisms associated with blepharospasm. Baker et al. identified blinking-induced functional magnetic resonance imaging (fMRI) activation patterns in five benign essential blepharospasm (BEB) patients and five age-matched control subjects and concluded that the activations observed might represent a hyperactive cortical circuit linking visual cortex, limbic system, supplementary motor cortex, cerebellum, and supranuclear motor pathways innervating the periorbital muscles \[[@B31]\]. Antal et al. examined whether magnetic or electrical stimulation of the brain could improve the involuntary closure of the eyelids in patients with blepharospasm or Meige syndrome \[[@B32]\].

Schizophrenia is a brain disorder that affects the way a person acts, thinks, and sees the world. People with schizophrenia have an altered perception of reality, often a significant loss of contact with reality. Chen et al. utilized a multivariate approach to identify genomic risk components associated with brain function abnormalities in schizophrenia \[[@B33]\]. They first derived 5157 candidate single nucleotide polymorphisms (SNPs) from genome-wide array based on their possible connections with schizophrenia and further investigated for their associations with brain activations captured with functional magnetic resonance imaging (fMRI) during a sensorimotor task. Then, they identified 222 SNPs which showed significant difference between 92 schizophrenia patients and 116 healthy controls. Their further pathway analysis showed that the genes associated with the identified SNPs participated in four neurotransmitter pathways: GABA receptor signaling, dopamine receptor signaling, neuregulin signaling and glutamate receptor signaling. Their finding is consistent with our inter-association analysis from the 369 brain-specific markers.

Our 16 pathways identified by inter-association analysis using IPAD contains 1) Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell, 2) Neuroactive ligand-receptor interaction, 3) GABAergic synapse, 4) GABA receptor activation, 5) Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity, 6) Neurotransmitter Release Cycle, 7) GABA synthesis, release, reuptake and degradation, 8) Class C/3 (Metabotropic glutamate/pheromone receptors), and 9) GABA A receptor activation etc.

The other 7 diseases (except Intestinal Obstruction) also show strong links with brain, such as Cataplexy \[[@B34]\], REM Sleep Behavior Disorder \[[@B35]\], Dystonic Disorders \[[@B36]\], Miosis \[[@B37]\], Brain Damage \[[@B38]\], Chronic \[[@B39]\], Affective Disorders \[[@B40]\], Psychotic \[[@B41]\], and Pupil Disorders \[[@B42]\].

The 7 identified drugs: 1) DB00349, Clobazam, 2) DB00475, Chlordiazepoxide, 3) DB00683, Midazolam, 4) DB00690, Flurazepam, 5) DB00842, Oxazepam, 6) DB01558, Bromazepam, and 7) DB01595, Nitrazepam have on average 63 inter-associations between pathway, disease, drug and organ. They show strong links with brain, such as 1) Clobazam \[[@B43]\], 2) Chlordiazepoxide \[[@B44]\], 3) Midazolam \[[@B45]\], 4) Flurazepam \[[@B46]\], 5) Oxazepam \[[@B47]\], 6) Bromazepam \[[@B48]\], and 7) Nitrazepam \[[@B49]\].

In conclusion, this case study shows that the self-validation of IPAD is an innovation of traditional enrichment analysis and can be useful for validating any pathways, diseases, drugs or organs that users identify with their own data and methods.

Case Study 2: Identification of previously undiscovered components by IPAD
--------------------------------------------------------------------------

RNA-seq is an emerging technology for surveying gene expression and transcriptome content by directly sequencing the mRNA molecules in a sample. RNA-seq can provide gene expression measurements and is regarded as an attractive approach to analyze a transcriptome in an unbiased and comprehensive manner. In this case study, we demonstrate the use of IPAD to identify previously undiscovered components by the enrichment analysis based on differentially expressed genes identified from the transcriptional profiling sequencing data \[[@B50]\]. The original purpose is to provide a general guide for analysis of gene expression and alternative splicing by deep sequencing. In the prostate cancer study, the prostate cancer cell line LNCap was treated with androgen/DHT. Mock-treated and androgen-stimulated LNCap cells were sequenced using the Illumina 1G Genome Analyzer. For the mock-treated cells, there were four lanes totaling \~10 million reads. For the DHT-treated cells, there were three lanes totaling \~7 million reads. All replicates were technical replicates. Samples labeled s1 through s4 are from mock-treated cells. Samples labeled s5, s6, and s8 are from DHT-treated cells. The read sequences are stored in FASTA files. The sequence IDs break down as follows: seq\_(unique sequence id)\_(number of times this sequence was seen in this lane). We first downloaded the publicly available transcriptional profiling sequencing data from the author\'s Web Site at <http://yeolab.ucsd.edu/yeolab/Papers.html> and computed the digital gene expression, next identified 278 differentially expressed genes in RNA-seq data from hormone treated prostate cancer cell line samples, then performed the enrichment analysis of the 278 genes with IPAD, and lastly carried out the inter-association analysis for these enriched components with IPAD.

In total, we identified 11 enriched pathways (p-value ≤ 5 × 10^-2^,*AE*≥ 3.45, *RE*≥ 1.95 and *MJI*≥ 0.040), 100 diseases(p-value ≤ 1.6 × 10^-3^, *AE*≥ 68.35, *RE*≥ 1.30 and *MJI*≥ 0.147), and 2 organs (p-value ≤ 1.9 × 10^-2^,*AE*≥ 4.38, *RE*≥ 5.45 and *MJI*≥ 0.080) for the 278 genes. And the further inter-association analysis of IPAD identified 10 pathways, 8 diseases, 2 drugs and 1 organs which are not previously discovered by the enrichment analysis of IPAD (Table [5](#T5){ref-type="table"}).

###### 

Identification of Previously Undiscovered Components by IPAD

  PathwayID      PathwayName                                               p-value     AE      RE      MJI     C
  -------------- --------------------------------------------------------- ----------- ------- ------- ------- ----
  1430728        Metabolism                                                4.32E-35    525     2.19    0.34    93
  556833         Metabolism of lipids and lipoproteins                     1.00E-13    175     2.25    0.27    91
  453279         Mitotic G1-G1/S phases                                    2.41E-42    47      27.44   0.33    87
  200137         AP-1 transcription factor network                         2.36E-06    44      2.97    0.32    87
  453279         Mitotic G1-G1/S phases                                    2.77E-09    78      2.73    0.30    87
  200120         Direct p53 effectors                                      6.09E-07    70      2.4     0.27    85
  69278          Cell Cycle, Mitotic                                       1.81E-14    166     2.37    0.28    82
  1640170        Cell Cycle                                                1.51E-12    183     2.11    0.26    80
  535734         Fatty acid, triacylglycerol, and ketone body metabolism   1.38E-07    81      2.35    0.26    79
  71291          Metabolism of amino acids and derivatives                 7.54E-15    120     2.9     0.33    76
                                                                                                               
  DiseaseID      DiseaseName                                               p-value     AE      RE      MJI     C
                                                                                                               
  MESH:D015228   Hypertriglyceridemia                                      1.60E-192   4573    2.09    0.77    79
  MESH:D009468   Neuromuscular Diseases                                    4.34E-07    117     2.04    0.41    74
  MESH:D009468   Neuromuscular Diseases                                    2.16E-293   4573    2.52    0.82    74
  MESH:D052016   Mucositis                                                 4.99E-199   4572    2.11    0.77    72
  MESH:D002543   Cerebral Hemorrhage                                       7.21E-128   4572    1.8     0.73    72
  MESH:D006463   Hemolytic-Uremic Syndrome                                 3.65E-215   4570    2.18    0.78    72
  MESH:D020246   Venous Thrombosis                                         6.59E-106   4573    1.71    0.72    70
  MESH:D013923   Thromboembolism                                           1.78E-123   4573    1.79    0.73    70
                                                                                                               
  DrugID         DrugName                                                  p-value     AE      RE      MJI     C
                                                                                                               
  PA449383       Docetaxel                                                 3.08E-02    52      1.89    0.36    24
  PA449780       Glutathione                                               1.74E-10    20      10.48   0.24    13
  PA131301952    Gefitinib                                                 8.52E-17    29.88   10.84   0.395   8
  PA451283       Rosiglitazone                                             7.73E-22    41.4    10.58   0.386   5
  PA448803       Carboplatin                                               2.57E-15    27      11.36   0.397   5
                                                                                                               
  OrganID        OrganName                                                 p-value     AE      RE      MJI     C
                                                                                                               
  liver          Liver                                                     1.82E-17    179     2.72    0.40    84

We found that some of these components that were previously undiscovered but identified by inter-association analysis still showed strong association with prostate cancer. For example, previous studies reported that the top 5 drugs we identified with inter-association analysis: docetaxel, glutathione, gefitinib, rosiglitazone, and carboplatin were all associated with prostate cancer. Docetaxel is a drug used in men whose prostate cancer no longer responds to hormone therapy. Tannock et al. compared docetaxel plus prednisone in men with advanced, hormone-refractory prostate cancer with mitoxantrone plus prednisone. They found that treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone, when given with prednisone \[[@B51]\]. The deficiency in the glutathione enzyme system has been proposed to increase the likelihood of developing both an enlarged prostate and prostate cancer. Nelson discovered a genetic defect in prostate cancer cell prevents the body from producing glutathione S-transferase (GST), an enzyme needed by the liver to detoxify harmful chemicals \[[@B52]\]. The function of a particular glutathione enzyme glutathione-S-transferase-pi-i (GSTP1) is almost universally lost in both cancerous and pre-cancerous prostate cells. The inactivation of this glutathione enzyme is an early event in the development of prostate cancer. Many studies have linked the loss of GSTP 1 to malignant transformation of prostatic tissues \[[@B52]\].

One study found that gefitinib and bicalutamide showed synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients \[[@B53]\]. Another study discovered that gefitinib-trastuzumab combination showed promising clinical activity in hormone refractory prostate cancer \[[@B54]\]. Smith et al. assessed the biological activity of rosiglitazone, a peroxisome proliferator-activated receptor gamma agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PSA) doubling time (PSADT) as the primary outcome variable and concluded that Rosiglitazone did not increase PSADT or prolong the time to disease progression more than placebo in men with a rising PSA level after radical prostatectomy and/or radiation therapy \[[@B55]\]. But Rosiglitazone was found to suppress human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways \[[@B56]\]. The number 3 drug, Carboplatin is a chemotherapy agent used for treatment of many types of cancer. Some studies examined the efficacy of carboplatin as a second line chemotherapy agent (after the failure of taxotere) as well as along with taxotere therapy for men with advanced prostate cancer \[[@B57],[@B58]\]. A phase II study assessed the outcome and predictive factors for prognosis and toxicity following intermittent chemotherapy with docetaxel, estramustine phosphate, and carboplatin (DEC) in patients with castrate resistant prostate cancer (CRPC) and found that combination chemotherapy with DEC has a potential effect on CRPC with acceptable toxicity \[[@B59]\]. Jeske et al. conducted a retrospective, bi-institutional review of patients with advanced CRPC treated with carboplatin plus paclitaxel after docetaxel and concluded that Carboplatin/paclitaxel chemotherapy following docetaxel in metastatic CRPC is well tolerated with favorable PSA response rates and survival and the combination is a viable option after progression on docetaxel-based therapy \[[@B60]\].

This case study shows that compared to traditional enrichment analysis, the IPAD\'s inter-association analysis can be more powerful and useful in identification of previously undiscovered pathways, diseases, drugs or organ specification.

Conclusion
==========

We developed IPAD as an integrated database system to analyze, identify, and validate pathway, disease, drug, organ specificity and their inter-associations. IPAD integrates many different types of pathway, disease, drug and organ-specificity information: pathway gene relationship from the BioCarta \[[@B4]\], KEGG \[[@B5]\], NCI-Nature curated \[[@B6]\], and Reactome \[[@B7]\] database; disease gene relationship from the CTD \[[@B17]\] and PharmGKB \[[@B18]\] database; drug gene relationship from the DrugBank \[[@B19]\] and PharmGKB \[[@B18]\] database; and organ-specific genes/proteins from the HOMER \[[@B20]\] databases.

Enriched pathways, diseases, drugs, organs and their inter-associations can be searched, displayed, and downloaded from our online user interface. The current IPAD database can help users address a wide range of pathway related, disease related, drug related and organ specificity related questions in human disease studies. We also developed a statistical method for similarity measurement and statistics and described two criteria for setting the threshold parameters, which can be extended to other enrichment applications. Lastly, our database was evaluated by comparison to other known databases, a constructed \"gold standard\" of 30161 known associations, and two case studies.

Discussion
==========

In this paper, we have demonstrated that IPAD can be used to discover, analyze, and validate pathway, disease, drug, and organ specificity from experimental data. We illustrated the features of IPAD by testing the inter-association between breast cancer markers related pathway, disease, drug and organ. In Case Study 1, we demonstrated the IPAD\'s ability to self-validate by using it to perform enrichment analysis and inter-association analysis on the 369 brain-specific markers. In Case Study 2, we further demonstrated the ability of IPAD to identify previously undiscovered components by the enrichment analysis based on differentially expressed genes identified from a prostate cancer study.

Selecting the appropriate statistical parameters for enrichment analysis and inter-association analysis is important. We presented a novel algorithm to measure relationships among the annotation terms based on p-value, Absolute Expression Value (*AE*), Relative Expression Value (*RE*) and Mean Jaccard Index (*MJI*). We also described the two criteria for setting the threshold parameters: 1) p-value below the 5% quantile and 2) 1 sigma lower control limits for *AE*, *RE*and *MJI*. However, defining each threshold parameter and implementing them effectively can be still challenging. Because the gene list size affects the enrichment score and the sizes of four types of component are largely different (Table [1](#T1){ref-type="table"}, 11663 molecules in 1956 Pathways, 17925 molecules in 6704 diseases, 3735 molecules in 5615 drugs, and 5599 molecules in 52 organs).

In our website we provide all results for users to cut off according to the specificity of their input data. The number of enriched component sets depends on the structure of the data and the problem space. If no enriched component sets or a very large number of enriched component sets pass the thresholds, users first check whether too few or too many genes are loaded. If there are no such issues, users can tighten up the thresholds for too many significant component sets and relax them for no significant component sets.

In this paper, we introduced organ-pathway, organ-disease, organ-drug, organ-organ inter-associations for the first time. An organ actually means organ specificity in the paper. An organ is a group of tissues that perform a specific function or group of functions. Organ specificity is referred as the specificity of level of expression of a gene or protein in a certain type of organ. Identification of the association of organ-gene, organ-pathway, organ-disease, organ-drug, and organ-organ can be helpful in the discovery potentially therapeutic genes related to specific organs, measuring and understanding the function and characteristics of cells and tissues in an organ from the perspective of cooperative network, disease diagnosis, and drug target, indicating important clues about gene function, network signaling, disease treatment and drug target, and monitoring organ integrity both during preclinical toxicological assessment and clinical safety testing of investigational drugs.

Methods
=======

Data sources
------------

We show an overview of the data integration process in Figure [1](#F1){ref-type="fig"}. Pathway data in IPAD were collected from the four most commonly used sources, i.e., BioCarta \[[@B4]\], KEGG \[[@B5]\], NCI-Nature curated \[[@B6]\], and Reactome \[[@B7]\].

The BioCarta \[[@B4]\] includes expert-curated interactive graphic models of many pathways from diverse fields like apoptosis, cell cycle, cell signaling, development, immunology, neuroscience, adhesion, and metabolism. BioCarta data from June 2004 was imported from its website.

The KEGG \[[@B5]\] pathway is a collection of manually drawn pathway maps containing the knowledge on the molecular interaction and reaction networks in Metabolism, Genetic Information Processing, Environmental Information Processing, Cellular Processes, Organismal Systems, Human Diseases, and Drug Development. The KEGG data was downloaded from its ftp site.

The NCI-Nature curated \[[@B6]\] are created by Nature Publishing Group editors and reviewed by experts in the field. Biomolecules are annotated with UniProt protein identifiers and relevant post-translational modifications. Interactions are annotated with evidence codes and references. The NCI-Nature curated data was downloaded from its website.

Reactome \[[@B7]\] is an expert-authored, peer-reviewed knowledgebase of human reactions and pathways that provides infrastructure for computation and data mining across the biologic reaction network. Human pathways from Reactome were downloaded from its website.

Disease data in IPAD was downloaded from two different sources: CTD \[[@B17]\] and PharmGKB \[[@B18]\]. The Comparative Toxicogenomics Database CTD \[[@B17]\] is a public website and research tool that curates scientific data describing relationships between chemicals, genes, and human diseases. The Pharmacogenetics Knowledge Base (PharmGKB) \[[@B18]\] is curate knowledgebase about the impact of genetic variation on drug response with focus on clinical interpretation of variants associated with drug response, drug dosing guidelines and genetic tests, drug-centered pathways, important PGx gene summaries, and relationships among genes, drugs and diseases.

Drug data in IPAD were downloaded from two different sources, DrugBank \[[@B19]\] and PharmGKB \[[@B18]\]. The DrugBank database \[[@B19]\] is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

The organ specificity in IPAD was downloaded from HOMER \[[@B20]\]. HOMER \[[@B20]\] is an integrated Human Organ-specific Molecular Electronic Repository, defining human organ-specific genes/proteins and covering about 22,598 proteins, 52 organs, and 4,290 diseases integrated and filtered from organ-specific proteins/genes and disease databases like dbEST \[[@B61]\], TiSGeD \[[@B62]\], HPA \[[@B63]\], CTD \[[@B17]\], and Disease Ontology \[[@B29]\].

We used PERL to parse the text data we downloaded and a light-weight implementation of the Document Object Model interface in Python 2.7.l \[[@B64]\], xml.dom.minidom to parse the XML format data.

Similarity measure for the inter-association analysis
-----------------------------------------------------

The Jaccard Index measures similarity between pathways, diseases, drugs and organs, and is defined as the size of the intersection divided by the size of the union of the component sets. The component similarity measure can be defined as the extent of overlaps, e.g., common number of genes/proteins, shared between two different components \[[@B65]\]. In IPAD, we have four types of components: pathway, disease, drug and organ.

The component-component similarity score JI*~i,j~*is defined as Jaccard Index,

$$JI_{i,j} = \frac{\left| P_{i} \cap P_{j} \right|}{\left| P_{i} \cup P_{j} \right|}i = 1...N,j = 1...M,$$

where, *N*, *M*denotes total number of components. *P~i~*and *P~j~*denote two different components, *P~i~*and *P~j~*can be the same or different type, while \|*P~i~*\| and \|*P~j~*\| are the numbers of molecules in these two components. Their intersection *P~i~*∩*P~j~*is the set of all molecules that appear in both *P~i~*and *P~j~*, while their union *P~i~*∪*P~j~*is the set of all molecules either appearing in the *P~i~*or in the *P~j~*. Duplicates are eliminated in the intersection set and union set.

Similarly, we define the left component-component similarity score LJI*~i,j~*as Left Jaccard Index,

$$LJI_{i,j} = \frac{\left| P_{i} \cap P_{j} \right|}{min\left( \left| P_{i} \middle| , \middle| P_{j} \right| \right)}i = 1...N,j = 1...M,$$

the right component-component similarity score RJI*~i,j~*as Right Jaccard Index,

$$RJI_{i,j} = \frac{\left| P_{i} \cap P_{j} \right|}{max\left( \left| P_{i} \middle| , \middle| P_{j} \right| \right)}i = 1...N,j = 1...M,$$

and the mean component-component similarity score MJI*~i,j~*as Mean Jaccard Index,

$$MJI_{i,j} = \frac{LJI_{i,j} + RJI_{i,j}}{2}i = 1...N,j = 1...M.$$

With the equations above, we can calculate similarity scores (Jaccard Index, Left Jaccard Index, Right Jaccard Index, and Mean Jaccard Index) for pathway-pathway, disease-disease, drug-drug, organ-organ, pathway-disease, pathway-drug, pathway-organ, disease-drug, disease-organ, and drug-organ associations.

Statistics for the inter-association analysis
---------------------------------------------

In addition to similarity scores, we developed a statistic model based on Fisher Exact test \[[@B66],[@B67]\] and number of genes involved in a component for systematic enrichment analysis. When members of two independent groups can fall into one of two mutually exclusive categories, Fisher Exact test \[[@B66],[@B67]\] is used to determine whether the proportions of those falling into each category differs by group. In IPAD enrichment system, Fisher Exact test is adopted to measure the gene-enrichment in annotation terms and the enrichment between components. Given *p*to be the probability of success in a Bernoulli trial where one gene in component *i*falls in component *j*, the probability of *x*successes is

$$P\left( x \right) = C_{L}^{x}p^{x}\left( {1 - p} \right)^{L - x},$$

Where *L*is the total number of genes in component *i*, *M*is the total number of genes in component *j*, *N*is the total number of genes in the type of component, *p*= *M*/*N*, *x*is the number of genes corresponding to component *i*in component *j*, and $C_{L}^{x}$ is the number of possible combinations of *x*genes from a set of *L*genes.

The p-value for component *i*in component *j*is the probability of obtaining a test statistic at least as extreme as the one observed, given that the null hypothesis that there is no enrichment between component *i*and component *j*is true, and calculated according to the following formula

$$Pvalve = \sum_{x}^{M}P\left( x \right).$$

To prevent multiple testing problem from happening, IPAD adjust the p-value by Benjamini & Hochberg method \[[@B68]\].

The absolute enrichment value (*AE*) of component *i*in component *j*is defined as *x*, the number of genes corresponding to component *i*in component *j*. The expected enrichment value (*EE*) of component *i*in component *j*is defined as the expected number of genes of component *i*in component *j*under the null hypothesis that the component *i*and component *j*are independent of each other.

$$EE = L \cdot \frac{M}{N}.$$

The relative enrichment value (*RE*) of component *i*in component *j*is defined as *AE*/*EE*.

We define inter-associations as enriched ones if they satisfy the thresholds in table [6](#T6){ref-type="table"} (i.e. for Pathway-Pathway association: p-value ≤ 2.13^-19^, *RE*≥ 3.131, *AE*≥ 9 and *MJI*≥ 0.328; and so on). We determine the parameters based on the following two criteria: 1) Associations with p-value below the 5% quantile are chosen as enriched associations based on the p-value distribution of inter-association in the Figure [2](#F2){ref-type="fig"} and the comparison of the five quantile thresholds in Table [7](#T7){ref-type="table"}. 2) 1-sigma limits (1-standard error) are used to set the lower control limits for *AE*, *RE*and *MJI*. There are no upper control limits for *AE*, *RE*and *MJI*. *AE*, *RE*and *MJI*must be greater than or equal to one standard deviation from their means. Associations falling below the lower control limits are considered to be not stably enriched.

###### 

Thresholds for Inter-association Analysis in IPAD

  Typea     Typeb     p-value≤   AE≥      RE≥     MJI≥
  --------- --------- ---------- -------- ------- -------
  pathway   Pathway   2.13E-19   9.000    3.131   0.328
  Pathway   Disease   1.28E-06   3.000    1.268   0.127
  Pathway   Disease   5.73E-04   2.168    2.133   0.193
  Pathway   Organ     5.00E-02   1.132    1.970   0.109
  Disease   Pathway   1.02E-05   3.000    1.254   0.140
  Disease   Disease   4.19E-72   73.538   1.370   0.393
  Disease   Drug      5.00E-02   2.000    1.422   0.171
  Disease   Organ     5.00E-02   1.000    1.313   0.121
  Drug      Pathway   1.60E-05   2.666    2.468   0.141
  Drug      Disease   6.51E-03   1.000    1.358   0.133
  Drug      Drug      1.59E-05   3.000    3.391   0.333
  Drug      Organ     5.00E-02   2.678    3.856   0.201
  Organ     Pathway   4.01E-02   1.000    2.018   0.056
  Organ     Disease   6.27E-03   2.000    1.384   0.085
  Organ     Drug      5.00E-02   2.206    3.093   0.155
  Organ     Organ     5.00E-02   7.000    4.279   0.095

###### 

A Comparison of the Five Quantile Thresholds

                \# Associations In Pathway   \#Associations In Disease   \#Associations In Drug   \#Associations In Organ   \#total   F_measure
  ------------- ---------------------------- --------------------------- ------------------------ ------------------------- --------- -----------
  Quantile 3%   111374                       594647                      119170                   3627                      828818    60.75%
  Quantile 4%   148455                       786699                      124467                   4471                      1064092   68.58%
  Quantile 5%   185474                       984366                      130029                   4471                      1304340   68.56%
  Quantile 6%   222175                       1176166                     135915                   4471                      1538727   68.18%
  Quantile 7%   259592                       1367923                     143947                   4471                      1775933   66.92%

P-value below the 5% quantile performs better than other p-value thresholds with a balanced F_measure and an appropriate total number of inter-associations (Table [7](#T7){ref-type="table"}). First, the threshold (p-value ≤ Quantile 3%) is too strict. It filters out about half of the inter-associations that are identified by the threshold (p-value ≤ Quantile 7%). Secondly, the thresholds (p-value ≤ Quantile 6%) and (p-value ≤ Quantile 7%) cannot perform better in F_measure than the threshold (p-value ≤ Quantile 5%). Finally, we choose (p-value ≤ Quantile 5%) as the best threshold because we can identify 23% more inter-associations with (p-value ≤ Quantile 5%) than with (p-value ≤ Quantile 4%), although the F_measure of the threshold (p-value ≤ Quantile 4%) is a little bit higher than that of the threshold (p-value ≤ Quantile 5%).

Further comparison between four sigma thresholds (Table [8](#T8){ref-type="table"}) shows that 1-sigma threshold to set the lower control limits for *AE*, *RE*and *MJI*can have the better prediction performance than other sigma thresholds.

###### 

A Comparison of the Four Sigma Thresholds

              \# Associations In Pathway   \#Associations In Disease   \#Associations In Drug   \#Associations In Organ   \#total   F_measure
  ----------- ---------------------------- --------------------------- ------------------------ ------------------------- --------- -----------
  0.5 Sigma   117535                       644957                      58579                    2222                      823293    60.58%
  1 Sigma     185474                       984366                      130029                   4471                      1304340   68.56%
  2 Sigma     223000                       1215652                     156337                   5329                      1600318   67.78%
  3 Sigma     223000                       1215652                     156337                   5329                      1600318   67.78%

Similarity measure and statistics for the enrichment analysis
-------------------------------------------------------------

If a user\'s gene list is treated as a component, then the similarity measures and the statistics for genes-pathway, genes-disease, genes-drug and genes-organ can be similarly computed with the equations in the sections: \"Similarity Measure for the Inter-association Analysis\" and \"Statistics for the Inter-association Analysis\".

Performance measurements
------------------------

A \"gold standard\" of 30161 inter-associations (247 Pathway-Drug; 274 Drug-Drug; 23659 Pathway-Disease; 405 Organ-Disease; 2826 Drug-Disease; 2750 Disease-Disease) was constructed from KEGG \[[@B5]\], CTD \[[@B17]\], PharmGKB \[[@B18]\], DrugBank \[[@B19]\], and Disease Ontology \[[@B29]\] for *performance evaluation purpose*only. The following measurements were involved in our evaluation. (1) Sensitivity (also called recall) is the proportion of actual positive pairs which are correctly identified; (2) Specificity measures the proportion of negative pairs which are correctly identified; (3) Precision is the probability of correct positive prediction; (4) F_measure is the harmonic mean of precision and recall; (5) Accuracy is the proportion of correctly predicted pairs.

$$\begin{matrix}
{Sensitivity = \frac{TP}{TP + FN}} \\
{Specificity = \frac{TN}{TN + FP}} \\
{Precision = \frac{TP}{TP + FP}} \\
{F\text{\_}measure = \frac{2*Precision*Sensitivity}{Precision + Sensitivity}} \\
{Accuracy = \frac{TP + TN}{TP + TN + FP + FN}} \\
 \\
\end{matrix}$$

Online IPAD server design
-------------------------

The online version of IPAD database is a typical 3-tier web application \[[@B69]\], with an SQL Server2008R2 database at the backend database service layer, Apache/PHP server scripts to the middleware application web server layer, and CSS-driven web pages presented on the browser.

The result tables derived from the data generation steps were imported into the SQL Server2008R2 database (Figure [7](#F7){ref-type="fig"}). The pathway-gene, disease-gene, drug-gene, organ-gene, pathway-disease, pathway-drug, pathway-organ, disease-drug, organ-disease, organ-drug tables enable users to query the database with different IDs.

![**Relational Metadata Model**. The datasets derived by the data generation pipeline are filled in gray.](1471-2105-13-S15-S7-7){#F7}
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